BioCryst Pharmaceuticals Inc

biocryst.com

BioCryst Pharmaceuticals (NASDAQ: BCRX) is a biopharmaceutical company that discovers and develops oral, small-molecule drugs targeting rare diseases. The filing excerpts provided do not contain sufficient detail to describe its revenue model, product portfolio, customer base, geographic footprint, competitive position, or financial metrics with the specificity required. Based solely on the available filing excerpt, no further supported claims can be made about BioCryst's business operations, revenue streams, or market position.

Peers: ACADIA Pharmaceuticals Inc Fate Therapeutics Inc Insmed Inc Prometheus Biosciences, Inc. Relay Therapeutics Inc Sage Therapeutics, Inc. Prokidney Corp Ultragenyx Pharmaceutical Inc Vir Biotechnology Inc

Source: SEC 10-K, filed 2026-02-26

Dive deeper

Financial Snapshot

Revenue

TTM

$885.7M

Gross Margin

TTM

97.79%

Net Income

TTM

-$458.0M

Current Assets

2026 Q1

$373.6M

Current Liabilities

2026 Q1

$195.4M

Current Ratio

2026 Q1

191.22%

Total Assets

2026 Q1

$465.1M

Total Liabilities

2026 Q1

$1.019B

Book Value

2026 Q1

-$553.8M

Cash

2026 Q1

$171.6M

P/E

Last 4 Quarters

N/A

Free Cash Flow

TTM

$310.4M

Stock Price

Market Cap: $2.656 Billion